

Anti-PD-1 (Cemiplimab), Human IgG4 Antibody

11/20

CATALOG NO.: A2249-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a human recombinant IgG4 monoclonal antibody that targets programmed cell death-1 (PD-1) protein. PD-1 is an important immune checkpoint protein expressed on activated T-cells, B-cells, and macrophages. Binding of PD-1 to its ligands PD-L1 and PD-L2 prevent T-cell activation and cytokine production. The monoclonal antibody binds to PD-1 on T-cells and prevents its interaction with the ligands, thereby reactivating T-cells and inhibiting tumor growth. The original monoclonal antibody is approved by the FDA to treat patients with metastatic cutaneous squamous cell carcinoma (CSCC) and those patients with locally advanced CSCC but are not candidates for curative surgery or curative radiation.

ALTERNATE NAMES: PD1, PD-1, CD279, SLEB2, hPD-1, hPD-I, hSLE1, PDCD1, HPD-L

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: Recombinant / IgG4, kappa

SOURCE: CHO cells

IMMUNOGEN: Human PD-1

CAS NUMBER: 1801342-60-8

MOLECULAR WEIGHT: 146 kDa

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C. Avoid freeze/thaw cycles

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-PD-1 (Nivolumab), Humanized Antibody (A1307)
 Anti-PD-1 (Camrelizumab), Humanized Antibody (A2132)
 Anti-PD-1 (Sintilimab), Human IgG4 Antibody (A2156)
 Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)
 Anti-PD-1 (Toripalimab), Humanized Antibody (A2161)

FOR RESEARCH USE ONLY! Not to be used on humans.